WELCOME > Product >
PNAClamp™ Mutation Detection Kit JAK2
JAK2 V617F mutation is found in patients with blood related disease such as Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. Ruxolitinib is effective as a JAK Inhibitor, so that it is a prognostic factor to determine drug response.
JAK2 V617F mutation detection makes easy to classify patients with MPD (Myeloproliferative Disease) as three levels of diagnostic certainty (possible, probable and definite) and to determine which signal transduction therapy is suitable for each patients. In addition, testing for JAK2 V617F mutation has been recommended as clinical tests by WHO(World Health Organization).
JAK2 V617F mutation detection makes easy to classify patients with MPD (Myeloproliferative Disease) as three levels of diagnostic certainty (possible, probable and definite) and to determine which signal transduction therapy is suitable for each patients. In addition, testing for JAK2 V617F mutation has been recommended as clinical tests by WHO(World Health Organization).
CAT NO.
PNAC-6001 (size: 25 tests)
DETAILS
Mutations | Size |
Exon 14 | 25 tests |
V617F (1849G>T) |
FEATURES
- 01High sensitivity and specificity even with small amount of DNA (1% LOD with 10 ng wild/mutant type mixed DNA)
- 02Real-Time PCR based ready-to-use kit
- 03Short running time (within 3 hours)
PROCEDURE
sample preparation
Extraction of Total DNA 
Amplification of target DNA by Real-Time PCR 
Analysis of Result
COMPATIBLE SAMPE TYPE
- Blood
COMPATIBLE Real-Time PCR machine
CFX96
(Bio-Rad)
LightCycler 480II
(Roche)
ABI7500
(Thermo Fisher Scientific)
ABI7900HT
(Thermo Fisher Scientific)
Rotor-Gene Q
(Qiagen)
